Navigation Links
Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
Date:11/12/2008

edominantly result in antibody responses to CMV have not proven highly effective in transplant patients. Vaccine approaches using live, attenuated viruses can induce both antibody and cellular immune responses, but pose a potential safety concern, particularly for immunocompromised patients, of causing the disease they are intended to prevent. Vical's novel DNA vaccine approach is designed to induce both antibody and cellular immune responses against specific features of the CMV virus without the risk of causing CMV disease. Vical's vaccine has received orphan drug designation for hematopoietic stem cell transplant and solid organ transplant patients.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Vical or others will continue developme
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
2. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
3. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
4. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
6. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
7. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
8. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
9. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... WASHINGTON , Sept. 16, 2014 The ... (NYSE: LLY ) today released results from ... that sheds light on the lupus journey and the ... also for lupus caregivers. The UNVEIL study, which involved ... the devastating impact lupus has on all aspects of ...
(Date:9/16/2014)... DIEGO , Sept. 16, 2014 Imprimis ... pharmaceutical company dedicated to delivering high quality and novel ... announced that Chief Executive Officer Mark Baum ... Annual Craig-Hallum Alpha Select Conference in New York City.  ... its Go Dropless™ campaign in ophthalmology. The presentation ...
(Date:9/16/2014)... NEW YORK , Sept. 16, 2014  Relmada ... therapies for the treatment of chronic pain, announced today ... Sloan Kettering Cancer Center (MSKCC) in a series of ... ER, a new tamper-resistant, extended release form of levorphanol. ... investigator for these studies. Dr. Pasternak ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... LEIDEN, The Netherlands, July 6 Three ... Therapeutics and InteRNA,Technologies - have joined public-private partnership TI ... on cancer and,inflammatory diseases, have a total budget of ... The new consortium, formed by Syncom, Synvolux Therapeutics, and,University ...
... , NEW YORK, June 30 Betsy McCaughey of the Committee ... hospital infection rates made available by the NYS Department of Health ... have the lowest infection rates - and steer clear of those ... , Betsy McCaughey, a Ph.D., founded RID in 2004 with a ...
Cached Medicine Technology:New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects 2
(Date:9/16/2014)... September 16, 2014 Today, Top 10 ... the most recommended suppliers for the webmasters for people ... save money at the same time. , As an ... ) has been offering useful products at low prices ... connected to multiple GB connections to ensure that there ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Recently, the ... compared a lot of SEO hosting suppliers and announced ... most recommended suppliers for webmasters from the USA, UK, ... products (including VPS and cloud hosting) without spending a ... easy to use shared SEO hosting plans come with ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Care ... Logistics™, a component of the Hospital Operating System™ ... match patient needs with staff capacity. For the ... understanding of actual nursing and other staff capacity. ... of patient-care needs, anticipated admissions, discharges and transfers, ...
(Date:9/16/2014)... Randy Dotinga HealthDay Reporter , ... pattern baldness may face a higher risk of developing an ... a new study suggests. But, the study authors noted ... pattern of baldness should be concerned. Their study only found ... It did not prove cause and effect. "It is ...
(Date:9/16/2014)... September 15, 2014 Combining a standard chemotherapy ... from dividing improves both the survival and response ... new study by UT Southwestern Medical Center cancer ... the chemotherapy drug cisplatin with pemetrexed - an ... showed promising results for advanced, persistent, or recurrent ...
Breaking Medicine News(10 mins):Health News:Top 10 Best SEO Hosting: These Companies Are The Best Cheap SEO Hosting Suppliers In 2014 2Health News:Great SEO Hosting Suppliers Announced By Top 10 Best SEO Hosting 2Health News:Care Logistics Launches Demand Logistics as Part of the Hospital Operating System 2Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 2Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 3Health News:Cancer-fighting cocktail demonstrates promising results as treatment for advanced cervical cancer 2
... different types of dementia, but these findings are shocking. We ... study", say researchers Elisabet Englund and Hans Brunnstrm at Lund ... from the cities of Lund and Malm. All of them ... period 1996-2006 and been diagnosed with some form of dementia. ...
... Boston and Google.org have found web-based search data to be ... of outbreaks of dengue, an emerging mosquito-borne virus found in ... capture of disease-related queries in near real time, it could ... affected by dengue respond more quickly to nascent epidemics. ...
... new test that identifies the specific type of tumour they ... at the University of Edinburgh hope this improved diagnosis will ... the most effective drugs. The Edinburgh team worked with ... each of which had a different genetic signature. ...
... Private health clinics across Canada providing weight-loss surgeries are ... and at the expense of quality patient care, according to ... Chaim Bell. "The private clinics in Canada offer ... banding the upper stomach to restrict food intake to patients ...
... Randy Dotinga HealthDay Reporter , MONDAY, May 30 ... are marketed heavily toward children and teens, a leading association ... kids. Young children and teens should avoid energy drinks ... issued Monday, and routine consumption of sports drinks should be ...
... Ill. Functional magnetic resonance imaging (fMRI) may provide ... researchers at Columbia University in New York City, who ... children. Results of their study appear online and in ... is a spectrum disorder characterized by repetitive behaviors and ...
Cached Medicine News:Health News:Difficulties in diagnosing dementia type 2Health News:Searching the web for dengue 2Health News:Targeted testing offers treatment hope for ovarian cancer patients 2Health News:Private weight-loss surgery clinics shedding quality patient care 2Health News:Pediatricians Group Raps Energy and Sports Drinks for Kids 2Health News:Pediatricians Group Raps Energy and Sports Drinks for Kids 3Health News:New research may lead to improved diagnosis of autism 2
Our most popular saline breast implant style for over 20 years. A full, rounded look that adds greater dimension to the breast....
This Implant enhances and restores the nasal contour, The large selection of sizes with a variety of flares and lengths allows for more individualized results...
Inquire...
... at the point of care: , Only 120 ... only 70 L of whole blood (all parameters except ... of sensor cassette , safePICO mixer ensures thorough and ... in 7 seconds) * Not ...
Medicine Products: